.

DBV Technologies reported 30.43M in Current Liabilities for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
DBV Technologies DBVT:US 30.43M 4.4M
Acadia Pharmaceuticals ACAD:US $ 117.68M 1.92M
Alnylam Pharmaceuticals ALNY:US $ 657.68M 51.72M
Amarin AMRN:US $ 361.57M 61M
Biomarin Pharmaceutical BMRN:US $ 464.73M 25.69M
Eleven Biotherapeutics EBIO:US $ 8.47M 3.09M
Esperion Therapeutics ESPR:US $ 82.28M 3.19M
Galectin Therapeutics GALT:US $ 10.89M 1.36M
Halozyme Therapeutics HALO:US $ 199.51M 87.82M
Insmed INSM:US $ 113.82M 11.43M
Intercept Pharmaceuticals ICPT:US $ 151.43M 0.39M
IONIS PHARMACEUT IONS:US $ 267.81M 39.36M
Neurocrine Biosciences NBIX:US $ 285.7M 32.2M
Ptc Therapeutics PTCT:US $ 567.37M 90.6M
Sarepta Therapeutics SRPT:US $ 545.57M 90.6M
Ultragenyx Pharmaceutical RARE:US $ 220.64M 53.4M
United Therapeutics UTHR:US $ 331.5M 38.9M
YTE INCY:US $ 926.67M 40.51M